Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Retained Earnings: 2024-2025

Historic Retained Earnings for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -$1.1 billion.

  • Kura Oncology's Retained Earnings fell 24.75% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 24.75%. This contributed to the annual value of -$895.4 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Retained Earnings amounted to -$1.1 billion in Q3 2025, which was down 7.27% from -$1.0 billion recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Retained Earnings registered a high of -$771.0 million during Q1 2024, and its lowest value of -$1.1 billion during Q3 2025.